Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 220
- 试验地点
- 2
- 主要终点
- The proportion of patients taking bisphosphonate therapy within 6 months of hip fracture
研究概览
简要总结
Patients with hip fractures have suffered the most devastating consequence of osteoporosis; and yet, they are rarely if ever tested or treated for the condition, even though they remain at high risk of recurrent fracture.
We hypothesize that, compared with usual care, an allied health professional-run osteoporosis service (case management) will be able to increase testing and treatment of osteoporosis in patients at high risk of fracture.
详细描述
Patients with hip fractures have suffered the most devastating consequence of osteoporosis; and yet, they are rarely if ever tested or treated for the condition, even though they remain at high risk of recurrent fracture.
We hypothesize that, compared with usual care, an allied health professional-run osteoporosis service (case management) will be able to increase testing and treatment of osteoporosis in patients at high risk of fracture.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •hip fracture patient > 50 years of age
- •able to give consent (or proxy consent available)
- •lives within health region
- •no contraindications to bisphosphonate therapy
排除标准
- •refuses to participate or consent
- •dementia or delirium without a proxy consent available
- •nursing home or longterm care
- •pathologic fracture
- •chronic glucocorticoid use
- •already receiving prescription osteoporosis treatment (calcium and vitamin D do not preclude inclusion)
结局指标
主要结局
The proportion of patients taking bisphosphonate therapy within 6 months of hip fracture
次要结局
- Proportion of patients taking prescription osteoporosis treatment at 6 months and 12 months
- Proportion in receipt of a BMD test at 6 months and 12 months
- Proportion still adherent to osteoporosis treatments at 6 months and 12 months
- Proportion of patients with recurrent fractures at 6 months and 12 months
- Cost effectiveness analyses